This page compares what is documented about CagriSema and Retatrutide, rather than ranking them by effect. What each molecule is, the sizes and prices actually carried, what the certificate covers, and how the two differ on the bench. Everything here is research-use-only material and we do not publish outcome, dosing or administration content for any compound in the catalogue.
What is CagriSema and what is Retatrutide?
CagriSema. CagriSema refers to cagrilintide and semaglutide studied in combination rather than to a single new molecule, which makes specification a question about two materials, not one.
Retatrutide. Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist, and peer-reviewed metabolic-research output on multi-receptor incretin pharmacology has grown every year since 2022.
How do CagriSema and Retatrutide compare on price and size?
| CagriSema | Retatrutide | |
|---|---|---|
| Sizes carried | 5 mg, 10 mg, 20 mg | 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg |
| From | $75.00 | $80.00 |
| Best price per unit | $7.50 / mg | $3.57 / mg |
| Availability | Backordered — waitlist | Backordered — waitlist |
| Certificate | Lot certificate on the product page | Lot certificate on the product page |
| Molecular formula | — | C221H342N46O68 |
| Molar mass | — | 4,731.3 g/mol |
| Source | — | — |
| Research area | combination metabolic pharmacology | incretin receptor pharmacology |
At their best sizes Retatrutide works out at $3.57 per mg against $7.50 for CagriSema — 2.1 times more for the mg. Vial prices start at $75.00 and $80.00 respectively, which is the number most people compare and the one that says least, because the two are not sold in the same sizes. Full sizes, tier pricing and the lot certificate sit on the CagriSema page and the Retatrutide page.
What is each one studied for?
What the published literature investigates, which is a different question from what either will do, and the only one of the two a supplier can answer.
CagriSema is studied in combination metabolic pharmacology research. Combination approaches are where much of the current incretin literature is concentrated.
Retatrutide is studied in incretin receptor pharmacology research. Incretin pharmacology remains one of the most active areas in metabolic research, with multi-receptor agonists drawing sustained attention in the primary literature.
Studied in the same area does not make two compounds interchangeable, and the research library holds the per-compound documentation.
Retatrutide vs CagriSema: how they differ on the bench
Retatrutide. Lyophilised retatrutide holds longest sealed, desiccated and dark; our storage guide covers why every degradation route accelerates the moment water enters the vial.
CagriSema. A combination listing should tell you what is in the vial and in what proportion. If it does not, the certificate is the place that answer has to come from.
What actually differs between Retatrutide and CagriSema
Molar mass is not published for both of these, so the mass-to-amount conversion below is left undone rather than estimated. Where a formula and a molecular weight exist they are in the table above, carried with the PubChem record they came from; where they are not, the lot certificate is the document that settles what the material is.
Both are released against a certificate reporting identity, purity by the stated method and net peptide content, readable before anything is bought.
Which is better, Retatrutide or CagriSema?
Neither Retatrutide nor CagriSema is ranked against the other here, and the refusal is deliberate. Better, safer and stronger are questions about effects in a living system, and we sell neither compound for use in one — why none of these pages ranks two compounds sets out the reasoning in full.
What it does instead, for these two:
- Retatrutide is the cheaper of the two per mg, at $3.57 against $7.50.
- CagriSema is carried in 3 sizes and Retatrutide in 8, and each lot carries its own certificate.
Every one of those is checkable before you buy.
Common questions
What is the difference between Retatrutide and CagriSema?
Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist, and peer-reviewed metabolic-research output on multi-receptor incretin pharmacology has grown every year since 2022. CagriSema refers to cagrilintide and semaglutide studied in combination rather than to a single new molecule, which makes specification a question about two materials, not one.
Which one should I choose?
CagriSema is carried in 5 mg, 10 mg, 20 mg and Retatrutide in 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, each lot with its own certificate. Which of those suits the work is yours to decide; everything here is research-use-only rather than guidance for use in a human or an animal.
Do both CagriSema and Retatrutide come with a certificate of analysis?
Neither is in stock at the moment, so in each case the certificate is the one attached to the lot that arrives. A certificate belongs to a lot, not to a product. It is linked from the product page, and reports identity, purity by the stated method, and net peptide content for the material actually in that lot.
Which is cheaper, Retatrutide or CagriSema?
Per mg, Retatrutide at $3.57 against $7.50, taking each one's best size. By vial they start at $75.00 for CagriSema and $80.00 for Retatrutide, which is the comparison most people make and the one that says least, because the two are not sold in the same sizes.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.